Skip to content
Aglatimagene besadenovec
Aglatimagene besadenovec is a gene pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
402 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C611637173185250
Prostatic hyperplasiaD011470EFO_0000284N4034856684
Urinary retentionD016055HP_0000016R33123
Urinary bladder neck obstructionD001748EFO_1000840N32.0112
Urinary tract infectionsD014552EFO_0003103N39.011
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lower urinary tract symptomsD059411EFO_00080081111720
AdenocarcinomaD00023011158
Liver neoplasmsD008113EFO_1001513C22.0213
Drug therapyD00435811
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GliomaD005910EFO_0000520325
Urinary bladder neoplasmsD001749C67134
GlioblastomaD005909EFO_0000515123
Pancreatic neoplasmsD010190EFO_0003860C25112
AstrocytomaD001254EFO_0000271112
Transitional cell carcinomaD002295112
NeoplasmsD009369C8011
Non-small-cell lung carcinomaD00228911
Liver transplantationD016031EFO_001068211
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50224
Lung neoplasmsD008175C34.9022
Ovarian neoplasmsD010051EFO_0003893C5611
MesotheliomaD008654C4511
Malignant pleural effusionD016066J91.011
EpendymomaD00480611
Uterine cervical neoplasmsD00258311
Colonic neoplasmsD003110C1811
Kidney neoplasmsD007680EFO_0003865C6411
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic diseasesD011469N42.977
Transurethral resection of prostateD02072844
Urinary incontinenceD014549HP_0000020R3233
PainD010146EFO_0003843R5222
ProstatitisD011472EFO_0003830N4122
Urologic neoplasmsD014571C64-C6822
InfectionsD007239EFO_000054422
Genetic predisposition to diseaseD02002222
Therapeutic embolizationD00462122
BiopsyD00170622
Show 35 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAGLATIMAGENE BESADENOVEC
INNaglatimagene besadenovec
Description
Aglatimagene besadenovec is a gene pharmaceutical. It is currently being investigated in clinical studies.
Classification
Gene
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL3544993
ChEBI ID
PubChem CID
DrugBank
UNII ID5Z72SSS34W (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 12 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
12 adverse events reported
View more details